Drug Trial Radar · NCT01836523
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,398
Actual
Start
Nov 2013
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
Interventions
liraglutideDrug
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
placeboDrug
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
liraglutideDrug
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
placeboDrug
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
liraglutideDrug
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
placeboDrug
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c (Glycosylated Haemoglobin)Time frame: Week 0, week 52
- Change From Baseline in Body WeightTime frame: Week 0, week 52
- Change From Baseline in Total Daily Insulin DoseTime frame: Week 0, week 52
Locations
182 sites in 17 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Encino, California
Novo Nordisk Investigational Site
Escondido, California
Novo Nordisk Investigational Site
Huntington Beach, California
Novo Nordisk Investigational Site
La Mesa, California
Novo Nordisk Investigational Site
Lancaster, California
Novo Nordisk Investigational Site
Monterey, California
Novo Nordisk Investigational Site
San Mateo, California
Novo Nordisk Investigational Site
San Ramon, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Fort Lauderdale, Florida
Novo Nordisk Investigational Site
Hialeah, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Marietta, Georgia
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Savannah, Georgia
Novo Nordisk Investigational Site
Idaho Falls, Idaho
Novo Nordisk Investigational Site
Indianapolis, Indiana
Novo Nordisk Investigational Site
Council Bluffs, Iowa
Novo Nordisk Investigational Site
Iowa City, Iowa
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Metarie, Louisiana
Novo Nordisk Investigational Site
Baltimore, Maryland
Novo Nordisk Investigational Site
Minneapolis, Minnesota
Novo Nordisk Investigational Site
Chesterfield, Missouri
Novo Nordisk Investigational Site
City of Saint Peters, Missouri
Novo Nordisk Investigational Site
Saint Charles, Missouri
Novo Nordisk Investigational Site
Springfield, Missouri
Novo Nordisk Investigational Site
St Louis, Missouri
Novo Nordisk Investigational Site
Billings, Montana
Novo Nordisk Investigational Site
Butte, Montana
Novo Nordisk Investigational Site
Lawrenceville, New Jersey
Novo Nordisk Investigational Site
Albany, New York
Novo Nordisk Investigational Site
Mineola, New York
Novo Nordisk Investigational Site
New York, New York
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.